Literature DB >> 23023988

The incident user design in comparative effectiveness research.

Eric S Johnson1, Barbara A Bartman, Becky A Briesacher, Neil S Fleming, Tobias Gerhard, Cynthia J Kornegay, Parivash Nourjah, Brian Sauer, Glen T Schumock, Art Sedrakyan, Til Stürmer, Suzanne L West, Sebastian Schneeweiss.   

Abstract

Comparative effectiveness research includes cohort studies and registries of interventions. When investigators design such studies, how important is it to follow patients from the day they initiated treatment with the study interventions? Our article considers this question and related issues to start a dialogue on the value of the incident user design in comparative effectiveness research. By incident user design, we mean a study that sets the cohort's inception date according to patients' new use of an intervention. In contrast, most epidemiologic studies enroll patients who were currently or recently using an intervention when follow-up began. We take the incident user design as a reasonable default strategy because it reduces biases that can impact non-randomized studies, especially when investigators use healthcare databases. We review case studies where investigators have explored the consequences of designing a cohort study by restricting to incident users, but most of the discussion has been informed by expert opinion, not by systematic evidence. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2012        PMID: 23023988     DOI: 10.1002/pds.3334

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  78 in total

1.  Counterpoint: the treatment decision design.

Authors:  M Alan Brookhart
Journal:  Am J Epidemiol       Date:  2015-10-26       Impact factor: 4.897

2.  Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; Susan Gruber; Ivan Zorych; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

3.  Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults.

Authors:  Mary E Tinetti; Ling Han; David S H Lee; Gail J McAvay; Peter Peduzzi; Cary P Gross; Bingqing Zhou; Haiqun Lin
Journal:  JAMA Intern Med       Date:  2014-04       Impact factor: 21.873

Review 4.  Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.

Authors:  Elisabetta Patorno; Elizabeth M Garry; Amanda R Patrick; Sebastian Schneeweiss; Victoria G Gillet; Olesya Zorina; Dorothee B Bartels; John D Seeger
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

5.  Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.

Authors:  Sebastian Haertter; Fenglei Huang; Lionel Riou Franca
Journal:  CMAJ       Date:  2017-02-27       Impact factor: 8.262

6.  Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.

Authors:  Andrew W Roberts; Stacie B Dusetzina; Joel F Farley
Journal:  J Comp Eff Res       Date:  2015-01       Impact factor: 1.744

7.  Long-term opioid therapy definitions and predictors: A systematic review.

Authors:  Ruchir N Karmali; Christopher Bush; Sudha R Raman; Cynthia I Campbell; Asheley C Skinner; Andrew W Roberts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-12-18       Impact factor: 2.890

8.  Evaluating the incident user design in the HIV population: incident use versus naive?

Authors:  Emily S Brouwer; Daniela C Moga; Joseph J Eron; Sonia Napravnik
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-09-25       Impact factor: 2.890

9.  Effectiveness of β-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease.

Authors:  Tara I Chang; Jingrong Yang; James V Freeman; Mark A Hlatky; Alan S Go
Journal:  J Card Fail       Date:  2013-03       Impact factor: 5.712

10.  Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study.

Authors:  Yaa-Hui Dong; Chia-Hsuin Chang; Li-Chiu Wu; Mei-Shu Lai
Journal:  Eur J Clin Pharmacol       Date:  2016-07-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.